Sanofi Not Distracted By M&A Chatter As It Gets Back On Par With Market Growth
Recent market interest shown in other OTC assets will not distract Sanofi from its long-term plan to overhaul its Consumer Healthcare business, says CEO Paul Hudson. And this plan is delivering results, with Sanofi back on par with the consumer health market, posting sales up by 5% in 2021.
You may also be interested in...
Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.
Pharma R&D VP Mathai Mammen acknowledges “pros and cons to remaining” as one company but dismissed “any meaningful downside” for the pharma business, which along with the device business will continue operating as J&J.
Poland becomes the first country in the world to allow erectile dysfunction treatment tadalafil to be bought without a prescription thanks to a successful Rx-to-OTC switch application from local player Adamed Pharma.